# Felix Wong

> Felix Wong is the co-founder and CEO of Integrated Biosciences, a Redwood City biotech using synthetic biology, optogenetics and explainable AI to discover small-molecule drugs for age-related disease. A physicist and mathematician by training with a Harvard PhD in applied physics, he led the team that reported the first new structural class of antibiotics discovered with explainable deep learning - published in Nature in 2023 - and pioneered the AI-driven discovery of senolytics. He was named to the Forbes 30 Under 30 in Healthcare and has authored more than 30 papers in journals including Nature, Science and Cell.

- **Role:** Co-Founder and CEO at Integrated Biosciences, Inc.
- **Organizations:** Integrated Biosciences, Inc., Massachusetts Institute of Technology (MIT), Broad Institute, Harvard University
- **Nationality:** American
- **Education:** Ph.D. in Applied Physics, Harvard University, Degrees in applied physics, computer science, and mathematics, Harvard University
- **Known for:** Led the team that discovered the first new structural class of antibiotics via explainable deep learning (Nature, 2023), effective against MRSA, Pioneered the first AI-driven discovery of senolytics, a class of investigational anti-aging drugs, Co-founded and leads Integrated Biosciences, which raised $17.2M in seed funding

## Career timeline

- **2019** — Earned Ph.D. in applied physics from Harvard University
- **2019-2022** — Postdoctoral fellow in James J. Collins' lab at MIT; NIH K25 awardee; later an independent fellow at the Broad Institute
- **2022** — Co-founded Integrated Biosciences with Max Wilson in September; James J. Collins chairs the Scientific Advisory Board
- **2023** — Company unveils synthetic biology / optogenetics platform to control the aging-associated stress response
- **2023** — Led team that reported the first new structural class of antibiotics discovered with explainable deep learning, published in Nature
- **2024** — Closed $17.2M seed round led by Sutter Hill Ventures; named to Forbes 30 Under 30 in Healthcare
- **2024** — Announced strategic research partnership with LVMH Recherche
- **2025** — Published 'Optogenetics-enabled discovery of integrated stress response modulators' in Cell

## Achievements

- Led the team that discovered the first new structural class of antibiotics via explainable deep learning (Nature, 2023), effective against MRSA
- Pioneered the first AI-driven discovery of senolytics, a class of investigational anti-aging drugs
- Co-founded and leads Integrated Biosciences, which raised $17.2M in seed funding
- Named to Forbes 30 Under 30 in Healthcare
- Authored 30+ scientific publications in Nature, Science, Cell and other top journals
- Built a synthetic-biology platform using optogenetics to control the integrated stress response, a hallmark of aging

## Latest updates

- **2025-07** — Published 'Optogenetics-enabled discovery of integrated stress response modulators' in Cell
- **2024-12** — Announced strategic research partnership with LVMH Recherche
- **2024-10** — Closed $17.2M seed round led by Sutter Hill Ventures to accelerate anti-aging drug development

## Links

- Website: https://integratedbiosciences.com
- LinkedIn: https://www.linkedin.com/in/felixjwong

---

Profile page: https://yespress.io/felix-wong
Published by YesPress — https://yespress.io
Last updated: 2026-06-24